The estimated Net Worth of Michael D West is at least $1.52 Million dollars as of 11 March 2023. Michael West owns over 3,125 units of AgeX Therapeutics Inc stock worth over $477,766 and over the last 21 years he sold AGE stock worth over $0. In addition, he makes $1,041,700 as Chief Executive Officer, Founder, and Director at AgeX Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Michael West AGE stock SEC Form 4 insiders trading
Michael has made over 26 trades of the AgeX Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,125 units of AGE stock worth $34,688 on 11 March 2023.
The largest trade he's ever made was exercising 1,470,400 units of AgeX Therapeutics Inc stock on 21 July 2014 worth over $735,200. On average, Michael trades about 43,011 units every 116 days since 2004. As of 11 March 2023 he still owns at least 43,042 units of AgeX Therapeutics Inc stock.
You can see the complete history of Michael West stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael West biography
Dr. Michael D. West Ph.D. serves as Chief Executive Officer, Founder, Director of the Company. Dr. West was appointed Chief Executive Officer of Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.) during October 2007 and then served as Co-Chief Executive Officer from October 2015 until September 2018. Dr. West also served as interim President and Chief Executive Officer of Asterias Biotherapeutics, Inc. from April 2014 to June 2014, and as Vice President of Technology Integration of Asterias until December 2015. Dr. West served as a director of: Lineage from 2002 until September 2018; Asterias from 2012 until September 2018; and OncoCyte Corporation from 2013 to 2016. Prior to becoming Chief Executive Officer of Lineage, Dr. West served as Chief Executive Officer, President, and Chief Scientific Officer of Ocata Therapeutics, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Dr. West also founded Geron Corporation of Menlo Park, California, and from 1990 to 1998, he was a Director and Vice-President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research between Geron and its academic collaborators, James Thomson and John Gearhart, which led to the first isolation of human embryonic stem and human embryonic germ cells. Dr. West received a B.S. from Rensselaer Polytechnic Institute in 1976, an M.S. in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging
What is the salary of Michael West?
As the Chief Executive Officer, Founder, and Director of AgeX Therapeutics Inc, the total compensation of Michael West at AgeX Therapeutics Inc is $1,041,700. There are no executives at AgeX Therapeutics Inc getting paid more.
How old is Michael West?
Michael West is 66, he's been the Chief Executive Officer, Founder, and Director of AgeX Therapeutics Inc since 2017. There are 3 older and 7 younger executives at AgeX Therapeutics Inc. The oldest executive at AgeX Therapeutics Inc is Judith Segall, 68, who is the Sec..
What's Michael West's mailing address?
Michael's mailing address filed with the SEC is 1101 MARINA VILLAGE PARKWAY, SUITE 201, , ALAMEDA, CA, 94501.
Insiders trading at AgeX Therapeutics Inc
Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West, and Judith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.
What does AgeX Therapeutics Inc do?
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
What does AgeX Therapeutics Inc's logo look like?
Complete history of Michael West stock trades at Oncocyte and AgeX Therapeutics Inc
AgeX Therapeutics Inc executives and stock owners
AgeX Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael West,
Chief Executive Officer, Founder, Director -
Dr. Michael D. West Ph.D.,
Founder, Pres, CEO & Director -
Dr. Michael D. West,
Founder, Pres, CEO & Director -
Nafees Malik,
Chief Operating Officer -
Gregory Bailey,
Independent Chairman of the Board -
Hal Sternberg,
Vice President - Research -
Dr. Nafees Naseer Malik M.D.,
Chief Operating Officer -
Eun-Jae Park CPA,
Chief Financial Officer -
Michael May,
Independent Director -
Annalisa Jenkins,
Independent Director -
Andrea Park,
Chief Financial Officer -
Judith Segall,
Sec. -
Dr. Ivan Labat,
Chief Information Officer -
Andrea Eun-Jae Park CPA,
Chief Financial Officer -
Judith Segall,
Director of Admin & Secretary -
Ltd Juvenescence,
Director -
John F Mauldin,
Director -
Michael H. Mulroy,
Director -
Joanne M. Hackett,
Director